Literature DB >> 28254409

The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.

Guangbing Xiong1, Mengyu Feng2, Gang Yang3, Suli Zheng4, Xujun Song5, Zhe Cao6, Lei You7, Lianfang Zheng8, Ya Hu9, Taiping Zhang10, Yupei Zhao11.   

Abstract

Pancreatic cancer, which is often asymptomatic, is currently one of the most common causes of cancer-related death. This phenomenon is most likely due to a lack of early diagnosis, a high metastasis rate and a disappointing chemotherapy outcome. Thus, improving treatment outcomes by overcoming chemotherapy resistance may be a useful strategy in pancreatic cancer. Various underlying mechanisms involved in the chemoresistance of pancreatic cancer have been investigated. Notably, non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a pivotal role in regulating sensitivity to chemotherapy in pancreatic cancer. In this review, we highlight recent evidence regarding the role of miRNAs and lncRNAs in the chemoresistance of pancreatic cancer, including their expression levels, targets, biological functions and the regulation of chemoresistance, and discuss the potential clinical application of miRNAs and lncRNAs in the treatment of pancreatic cancer.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Long non-coding RNA; Mechanism; Pancreatic cancer; microRNA

Mesh:

Substances:

Year:  2017        PMID: 28254409     DOI: 10.1016/j.canlet.2017.02.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

Review 1.  Exosomal biomarkers for cancer diagnosis and patient monitoring.

Authors:  Amy Makler; Waseem Asghar
Journal:  Expert Rev Mol Diagn       Date:  2020-02-20       Impact factor: 5.225

Review 2.  Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications.

Authors:  Jiangdong Qiu; Gang Yang; Mengyu Feng; Suli Zheng; Zhe Cao; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Mol Cancer       Date:  2018-01-05       Impact factor: 27.401

3.  Microarray expression profile analysis of circular RNAs in pancreatic cancer.

Authors:  Shixiang Guo; Xuejun Xu; Yongsheng Ouyang; Yunchao Wang; Jiali Yang; Liangyu Yin; Jiayun Ge; Huaizhi Wang
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

4.  A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma.

Authors:  Yang Yu; Xiao Feng; Shundong Cang
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

5.  Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo.

Authors:  Yu Wei Deng; Wen Jing Hao; Yi Wen Li; Yi Xin Li; Bo Chen Zhao; Dan Lu
Journal:  J Breast Cancer       Date:  2018-09-12       Impact factor: 3.588

6.  lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Lei Chen; Jie Liu; Tong Tang; Yong-Chuan Zhang; Ming-Zhong Liu; Li-Ya Xu; Jun Zhang
Journal:  Onco Targets Ther       Date:  2018-11-09       Impact factor: 4.147

7.  H3K27ac-induced lncRNA PAXIP1-AS1 promotes cell proliferation, migration, EMT and apoptosis in ovarian cancer by targeting miR-6744-5p/PCBP2 axis.

Authors:  Yimin Ma; Wei Zheng
Journal:  J Ovarian Res       Date:  2021-06-09       Impact factor: 5.506

Review 8.  Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts.

Authors:  Fengming Yang; Zhiqiang Ning; Ling Ma; Weitao Liu; Chuchu Shao; Yongqian Shu; Hua Shen
Journal:  Mol Cancer       Date:  2017-08-29       Impact factor: 27.401

Review 9.  The emerging role of long non-coding RNA in spinal cord injury.

Authors:  Zhongju Shi; Bin Pan; Shiqing Feng
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

10.  MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

Authors:  Guangbing Xiong; Hua Huang; Mengyu Feng; Gang Yang; Suli Zheng; Lei You; Lianfang Zheng; Ya Hu; Taiping Zhang; Yupei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2018-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.